Unlike most well known diseases for which thousands of scientists and hundreds of million of euros are being invested in research, levels of funding for ALS research is insufficient and as a result the cause of this disease remains unknown and no effective treatment exists
So much needs to be discovered in the field of ALS!
The only therapeutic drug available for ALS today, Riluzole, was identified 12 years ago, in 1995 but this drug is largely ineffective.
We can only hope for significant progress to be made in ALS research if we really tackle the problem without restraint in collaborative fashion.
Money is key and instrumental for accelerating research; it will eventually lead to the saving of lives.
Funding for Thierry Latran Foundation has relied on his pragmatism. He set up the Foundation under the ageis of the Fondation de France and its equivalent abroad in June 2008.
This means that:
The Foundation’s accounts are certified and governed by the Fondation de France. All money donated to the Foundation will be dedicated to basic ALS research and administrations expenses will be kept to a minimum.
Transnational gifts are welcomed through the Transnational Giving Europe Network. Donors can benefit from their own country rules for exemption of taxes. Please contact us to identify the Foundation partnership/partnering? in your country.
80 donors have already committed to invest up to 7 million Euros over the next 10 years. This represents a considerable amount.
However, this is not enough!
In order to make a significant impact in ALS research we aim to reach more than € 2 Millions per year.
Thierry Latran Foundation warmly thanks Frieh & Associés for it’s great contribution to set up the Foundation RISC GROUP & SALTIMBANQUE for their great contribution to this website